If you’re leading market access, HEOR, or commercial analytics at a pharma or medtech company, you’ve probably hit this wall: You need real-world evidence from insurance claims to complement your clinical trials… but privacy regulations have turned data access into a compliance minefield.
Here’s what’s actually happening in late 2025. The FDA just finalized guidance that removes a major barrier—they’re no longer requiring individual patient-level data for many regulatory submissions using real-world evidence. And that’s fundamentally changing how aggregated insurance claims data moves from “supportive” to “pivotal” evidence.
But there’s another shift that’s equally important. Synthetic insurance data—AI-generated datasets that statistically mimic real claims without containing any actual patient information—is gaining regulatory acceptance for applications like synthetic control arms in rare disease trials. The EMA’s been exploring this throughout 2024 and 2025, and we’re seeing real approvals happening.
So if you’re building your RWE strategy, you need to understand both of these data types. Not just what they are (we’ll get to that), but how they solve different problems, where regulators actually accept them, and—critically—how they keep you compliant with HIPAA in the US and GDPR in Europe.
Why Insurance Claims Data Became Essential for Pharma & Medtech
Randomized clinical trials have always been the gold standard. But you already know their limitations—small sample sizes, strict inclusion criteria that exclude the patients you’ll actually treat, short durations that miss long-term outcomes. And they’re expensive. We’re talking potential $1 billion+ over a product lifecycle expensive.
That’s why pharma and medtech companies have been moving toward real-world evidence derived from insurance claims for years now. The 21st Century Cures Act (2016) essentially mandated this shift by requiring the FDA to develop a framework for using RWE to support regulatory decisions.
Insurance claims data—specifically from payers like Medicare, Medicaid, commercial insurers, and statutory health insurance systems—captures what actually happens when your drug or device enters routine clinical practice. You get longitudinal patient journeys across multiple providers, something fragmented EHRs simply can’t deliver. And you’re looking at nationally representative populations, not the highly selected trial cohorts.
But (and this is a big but) accessing this data while staying compliant with privacy regulations became increasingly complex. HIPAA in the US has strict de-identification requirements. GDPR in Europe is even stricter, with explicit consent mandates and harsh penalties for breaches. Many companies found themselves locked out of valuable data sources entirely.
What Aggregated Insurance Data Actually Means
When we talk about aggregated insurance data, we’re referring to de-identified and pooled claims from multiple payers. This isn’t individual patient records—that would be a HIPAA violation. Instead, it’s claims data that’s been processed using either Safe Harbor or Expert Determination methods outlined in HHS guidance on de-identification.
The Safe Harbor method removes 18 specific identifiers (names, addresses, dates except year, etc.). Expert Determination uses statistical analysis to ensure re-identification risk is very small. Both approaches create datasets that are no longer considered protected health information under HIPAA.
What you get is longitudinal claims showing diagnoses (coded as ICD-10), procedures (CPT, HCPCS codes), prescriptions (NDC codes, often mapped to ATC classification for international work), and healthcare utilization patterns. You can track patient cohorts over time, but you can’t identify individual patients.
Real-World Coverage and Representativeness
The value of aggregated claims data comes from scale and representativeness. All-payer claims databases combine data from Medicare, Medicaid, commercial insurers, and statutory health insurance systems to create nationally representative views of treatment patterns, outcomes, and costs. This is population-level epidemiology that trials simply cannot provide.
Coverage breadth varies dramatically across data sources. Some maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types, while others focus on specific geographies or populations with greater clinical depth. Understanding which coverage model aligns with your research questions is critical—and often requires expertise that most companies lack internally.
Now, here’s something you need to understand upfront: claims data reflects billed and reimbursed care. That means you’re potentially underrepresenting uninsured populations, off-label use that wasn’t billed with the appropriate codes, and physician samples that never hit a pharmacy claim. These aren’t dealbreakers—they’re just limitations you need to account for when designing your RWE studies.
Synthetic Insurance Data: The Next Evolution
Synthetic insurance data takes a different approach entirely. Instead of de-identifying real claims, you’re using AI—specifically Generative Adversarial Networks (GANs) or similar techniques—to generate datasets that statistically mimic real claims patterns but contain zero actual patient information.
Think of it this way: you train an algorithm on real claims data to learn the relationships between diagnoses, treatments, outcomes, demographics, and costs. Then you generate synthetic patients that preserve these statistical relationships while containing no traceable link to any real individual. The re-identification risk isn’t just “very small”—it’s essentially zero because there’s no original patient to re-identify.
This matters tremendously under GDPR. While aggregated/de-identified data still falls under GDPR if there’s any theoretical re-identification risk, truly synthetic data can be argued to fall outside GDPR’s scope entirely since it doesn’t relate to identified or identifiable natural persons. That’s a compliance game-changer for companies operating in Europe.
Where Synthetic Data Shines (And Where It Doesn’t)
Synthetic data excels at solving specific problems. You can augment underrepresented populations—pediatric patients, pregnant women, rare disease cohorts—without privacy concerns. You can share datasets across organizations for AI model training without data use agreements that take six months to negotiate. And you can simulate scenarios that haven’t happened yet in your real claims data.
But synthetic data has limitations. The quality depends entirely on the training data—garbage in, garbage out. If your source claims have coding errors, missingness, or bias, your synthetic data will amplify those issues. And you need to validate that your synthetic populations actually preserve the causal relationships and outcome distributions that matter for your research question.
That’s why the emerging best practice in 2025 is hybrid approaches: use aggregated real claims as your foundation for established patterns and outcomes, then augment with synthetic data where you need additional statistical power for rare events or underrepresented subgroups.
Regulatory Acceptance: Where We Stand in 2025
The regulatory landscape shifted dramatically in December 2025. The FDA released its final guidance on using real-world evidence for medical devices, and here’s the critical change: they’re no longer requiring individual patient-level data in many cases where aggregated claims-derived RWE can demonstrate safety and effectiveness.
This builds on the FDA’s earlier RWE framework from 2018 and their 2021 guidance on assessing medical claims data. What was once “supportive evidence” is now accepted as pivotal evidence for certain regulatory decisions—label expansions, post-marketing requirements, and even supporting approvals in areas where randomized trials aren’t feasible.
Synthetic Controls and External Comparators
The really interesting development is around synthetic control arms. Research by Thorpe et al. (2020) documented early FDA approvals using synthetic controls derived from historical claims and registry data. We’ve seen this in oncology and rare diseases where placebo groups are ethically problematic or recruitment is nearly impossible.
Several regulatory approvals have demonstrated the viability of external comparators from historical claims—real-world examples of how aggregated data can replace traditional control arms. More recently, we’re seeing similar approaches for rare diseases where you simply can’t recruit enough patients for a traditional trial.
The EMA has been more cautious but increasingly supportive. Their 2024 reflection paper on RWD acknowledges synthetic augmentation and provides considerations for GDPR-compliant approaches. And pilot results from Prilla et al. (2024) show positive outcomes from integrating RWE into EU regulatory decisions using privacy-compliant data sources.
But—and this is important—pure synthetic control arms still face scrutiny. Regulators want to see validation that your synthetic populations preserve causally relevant relationships, not just statistical correlations. The bar is high, and you need strong methodological documentation.
Six Critical Applications Where These Data Types Deliver Value
1. Real-World Treatment Patterns and Patient Journeys
This is where aggregated claims data absolutely dominates. You can track complete patient journeys across providers, something EHRs struggle with due to fragmentation. You see dosing patterns in routine care, adherence issues, treatment switching, polypharmacy, and combination therapy use.
For pharma, this informs market access strategies, label expansion opportunities, and understanding of off-label prescribing patterns. For medtech, it’s tracking device utilization, procedure volumes, and adoption curves by geography and facility type. You’re not guessing at market dynamics—you’re measuring them directly from payer data.
I’ve worked with commercial analytics teams who discovered that their specialty drug was being discontinued 40% more frequently than competitors due to tolerability issues they hadn’t seen in trials. That’s the kind of insight that only comes from real-world longitudinal claims, and it directly informed their patient support program redesign.
2. Effectiveness, Safety, and Outcomes (RWE Generation)
Clinical trials tell you efficacy under ideal conditions. Insurance claims tell you effectiveness in real-world populations with comorbidities, polypharmacy, and variable adherence. This is real-world evidence generation that supports pharmacovigilance, HEOR, and post-marketing surveillance.
Aggregated claims enable detection of rare adverse events in large populations—safety signals you’d never see in a trial with a few thousand patients. And you can conduct comparative effectiveness research to demonstrate your product’s value versus competitors, critical evidence for payer negotiations and HTA submissions.
Here’s where synthetic data adds value: augmenting rare events or underrepresented subgroups. If you’re studying a rare adverse event in elderly diabetic patients and your claims only have 50 cases, you can generate synthetic cases that preserve the relevant comorbidity and medication patterns while increasing your statistical power. Just make sure you validate that your synthetic augmentation doesn’t introduce bias.
3. Epidemiology and Disease Burden Insights
Population-level epidemiology from all-payer claims provides nationally representative views of disease prevalence, incidence, progression, and comorbidity patterns. This is fundamental for pharma market sizing, identifying unmet needs, and prioritizing development pipelines.
You can see which therapeutic areas have the largest treatment gaps, which patient populations are underserved, and where your product could have the biggest impact. And unlike market research surveys with small samples and response bias, you’re looking at actual utilization from millions of covered lives in comprehensive multi-payer databases.
The granularity matters too. You can stratify by geography (which regions have the highest disease burden?), demographics, insurance type, and comorbidities. This level of detail informs everything from clinical trial site selection to commercial launch planning.
4. Health Economics and Market Insights
HEOR teams live and breathe aggregated claims data. You need it for cost-effectiveness analyses, budget impact models, resource utilization studies, and demonstrating value to payers. Claims show you the full economic picture: drug/device costs, but also hospitalizations, ER visits, specialist consultations, ancillary services.
For medtech companies, claims reveal device adoption curves, procedure volumes by facility type, geographic variation in utilization, and payer coverage patterns. You can identify early adopter markets, understand reimbursement barriers, and build launch strategies based on actual utilization data rather than projections.
Synthetic data plays a role here too—especially for scenario modeling. What happens to healthcare costs if your device achieves 20% market share versus 40%? You can simulate different adoption curves and reimbursement scenarios using synthetic populations that preserve real-world cost distributions without needing to wait years for actual data.
5. AI/ML Model Development and Testing
Data science teams increasingly need large-scale claims data to train predictive models for patient risk stratification, outcomes prediction, treatment response modeling, and more. But sharing real patient data across organizations for AI development creates HIPAA and GDPR nightmares.
Synthetic insurance data solves this. You can share datasets for algorithm development, run hackathons, collaborate with academic partners, and test models without data use agreements that take forever to negotiate. The AI can be trained on synthetic data that preserves statistical relationships while eliminating privacy risk.
But—critical caveat—you need to validate your models on real held-out test data before deployment. Synthetic training data is fantastic for initial development, but model performance can degrade if your synthetic generation process didn’t perfectly capture all the nuances of real clinical patterns.
6. Clinical Trial Design and Optimization
Claims data informs trial feasibility—which sites have enough eligible patients? What are realistic recruitment timelines? What comorbidities and concomitant medications should your inclusion/exclusion criteria account for?
More advanced applications include creating synthetic control arms using historical claims data, particularly for rare diseases or oncology where placebo groups are unethical. You can also augment underrepresented demographics in your trial planning—simulate what your trial population would look like with better pediatric or diverse ethnic representation.
I’ve seen pharma companies reduce their trial size by 30% by using historical claims-based external controls, saving millions in trial costs and months in recruitment time. That’s transformative when you’re racing to get a rare disease treatment to patients.
Aggregated vs. Synthetic: A Framework for Choosing
Both data types solve privacy problems, but they excel at different use cases. Here’s how to think about the decision:
| Aspect | Aggregated Claims Data | Synthetic Insurance Data |
|---|---|---|
| Privacy Risk | Low (de-identified under HIPAA Safe Harbor or Expert Determination) | Near-zero (no real patient information) |
| Data Volume & Representativeness | High (nationally representative all-payer claims from millions of lives) | Flexible (can augment rare events or underrepresented groups) |
| Regulatory Acceptance | Established for RWE submissions, label expansions, post-market surveillance | Growing acceptance for synthetic controls, AI training; still scrutinized for pivotal evidence |
| Data Quality Concerns | Missingness, coding errors, billing focus limits clinical detail | Depends entirely on training data quality; risk of amplifying bias |
| Best For | Longitudinal outcomes, epidemiology, real-world treatment patterns, HEOR | AI training, rare event augmentation, scenario modeling, cross-org collaboration |
| Cost Considerations | Premium databases expensive; requires data engineering and validation | Generation requires AI expertise; validation costs similar |
The emerging best practice is hybrid approaches. Use aggregated real claims as your foundation—that’s your ground truth for established outcomes, treatment patterns, and epidemiology. Then augment strategically with synthetic data where you need additional power for rare subgroups, want to simulate scenarios, or need to share data without privacy constraints.
Privacy Compliance: HIPAA vs. GDPR Considerations
Navigating privacy regulations is honestly one of the biggest pain points companies mention when evaluating these data sources. HIPAA and GDPR have different philosophies, and if you’re a global company, you need to comply with both.
HIPAA De-Identification Standards
Under HIPAA, properly de-identified data is not protected health information (PHI). The HHS guidance on de-identification outlines two acceptable methods:
Safe Harbor removes 18 specific identifier types—names, geographic subdivisions smaller than state (except first three digits of zip code if area has 20,000+ people), all dates except year for people over 89, phone numbers, fax numbers, email addresses, social security numbers, medical record numbers, health plan numbers, account numbers, certificate/license numbers, vehicle identifiers, device identifiers, URLs, IP addresses, biometric identifiers, full-face photos, and any other unique identifying characteristic.
Expert Determination requires a qualified statistician to analyze the data and determine that the risk of re-identification is very small. This method allows retaining more granular information (like precise dates or smaller geographic areas) if the expert can demonstrate low re-identification risk through statistical analysis.
Most aggregated claims databases use Safe Harbor because it provides a clear, defensible standard. But if you need more granular data for your research, Expert Determination might be worth pursuing with your data partners.
GDPR’s Stricter Requirements
GDPR takes a different approach. Data is “personal data” if it relates to an identified or identifiable natural person—and “identifiable” is interpreted broadly. Even if you’ve removed direct identifiers, GDPR considers whether someone could theoretically re-identify individuals by combining your dataset with other available information.
This creates uncertainty. Aggregated claims data that’s compliant under HIPAA might still be considered personal data under GDPR if there’s any theoretical path to re-identification. That means GDPR protections (consent requirements, breach notifications, data subject rights) might still apply.
The EMA’s guidance on RWE acknowledges this challenge and suggests approaches like differential privacy, additional aggregation, and synthetic data generation to reduce re-identification risk below GDPR’s threshold.
That’s where synthetic data becomes particularly valuable for European operations. Truly synthetic data that contains no traceable link to real individuals can be argued to fall outside GDPR’s scope entirely. But you need robust documentation proving your generation methodology doesn’t allow reverse-engineering to real patients.
State Laws and Emerging Regulations
Don’t forget state privacy laws in the US. California’s CCPA, Virginia’s CDPA, and similar laws in other states fill gaps where HIPAA doesn’t apply (particularly for non-covered entities). These laws often have their own de-identification standards and consumer rights that you need to navigate.
And the EU Health Data Space (EHDS) regulation is coming—it will create new frameworks for secondary use of health data across the EU, potentially streamlining access while imposing additional safeguards. Stay tuned for developments in 2026.
Understanding Your Data Partnership Options
The challenge many pharmaceutical companies face isn’t finding data sources—it’s determining which combination of capabilities aligns with their strategic priorities and specific use cases.
Key Dimensions of Variation Across Data Sources
Coverage and Scale: Data sources vary dramatically in their population coverage. Some maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types (Medicare, Medicaid, commercial). Others focus on specific geographies, therapeutic areas, or populations with greater clinical depth. The question isn’t which is “better”—it’s which coverage model matches your research questions.
Data Recency and Update Frequency: Some sources provide near-real-time data with monthly updates, enabling rapid signal detection and market monitoring. Others use adjudicated claims with 3-6 month lags but higher accuracy and completeness. Your choice depends on whether you need current intelligence or historical rigor.
Analytical Sophistication: Capabilities range from traditional query-based systems requiring significant data engineering expertise to AI-powered platforms offering self-service analytics and predictive modeling. Some provide raw data requiring in-house analysis; others offer full-service research support. The gap between licensing claims data and extracting actionable intelligence is substantial—this is where the right partner capabilities become critical.
Data Integration and Linkage: Some sources combine claims with complementary data—lab results, specialty pharmacy, provider characteristics, social determinants of health—for richer patient profiles. This vertical integration creates analytical possibilities that pure claims data cannot support. Others focus on claims purity but offer robust linkage methodologies to external datasets you control.
Therapeutic Area Depth: While many databases offer broad coverage, some specialize in specific areas—oncology, rare diseases, cardiovascular—with enhanced coding, treatment pathway documentation, and clinical validation. For specialized therapeutic work, this depth often outweighs breadth.
Cost Models and Licensing: Pricing structures vary enormously. Some charge by data volume, others by user seats, others by project scope. Subscription models, one-time licensing fees, and usage-based pricing each have implications for your total cost of ownership. Understanding these models requires experience with multiple vendor negotiations.
What to Look For in Claims Data Quality
Not all claims data is created equal. Here are critical quality dimensions that separate adequate from excellent sources:
Validation and Completeness: Ask about validation against external benchmarks, completeness percentages for key data elements (diagnoses, procedures, prescriptions), and error rates. Claims data quality varies significantly, and poor quality undermines every downstream analysis.
Longitudinal Tracking: The ability to follow patients over time depends on consistent enrollment tracking and patient linkage methodologies. Some databases maintain patient continuity even as individuals switch payers; others lose patients during transitions. For studies requiring longitudinal views, this is make-or-break.
Coding Accuracy: Billing-driven claims data suffers from upcoding, downcoding, and outright errors. Sources with clinical validation layers, algorithm-based correction, and ongoing quality monitoring deliver more reliable results for clinical questions.
Missingness Patterns: Understanding what’s systematically missing—outpatient labs, physician samples, cash-pay transactions, bundled procedure details—helps you design studies that work within data limitations rather than discovering gaps mid-analysis.
Navigating the Decision: Where Expert Guidance Becomes Critical
Understanding the landscape dimensions is one thing. Mapping your specific use cases to the right combination of data sources, analytical capabilities, and partnership models is another entirely.
Most pharmaceutical companies lack internal expertise in both the evolving vendor landscape and the nuances of claims data quality across different sources. The result is often costly mismatches—licensing data that doesn’t answer your questions, choosing self-service platforms when you need research support, or overpaying for capabilities you don’t need.
Expert advisors who understand both your business objectives and the data ecosystem can accelerate your path to value while avoiding common pitfalls. They help you:
- Define requirements clearly before evaluating options, ensuring you compare on dimensions that actually matter
- Navigate trade-offs between coverage, recency, analytical tools, and cost
- Identify which combination of data sources addresses your portfolio of use cases
- Negotiate favorable licensing terms based on market knowledge
- Avoid vendor lock-in while building long-term capabilities
The complexity of the modern RWE landscape—with dozens of overlapping data sources, rapidly evolving analytical platforms, and changing regulatory guidance—makes informed vendor selection increasingly difficult without specialized expertise.
Common Pain Points (And How to Address Them)
After working with dozens of pharma and medtech companies on their RWE strategies, I’ve seen the same challenges come up repeatedly. Let me walk through the most persistent pain points and what’s actually working to mitigate them.
Data Quality and Completeness Issues
Claims data is fundamentally created for billing, not research. That means you’re dealing with missing procedure codes, incomplete records from bundled payments, inaccuracies in medication exposure (physician samples don’t generate claims), and clerical coding errors that can be significant.
The solution isn’t to avoid claims data—it’s to validate rigorously and understand your limitations. Work with data partners who provide detailed quality metrics. Validate your findings against external benchmarks where possible. And be transparent about data limitations in your regulatory submissions and publications.
For certain use cases, consider supplementing claims with other data sources. Linking to lab data, clinical registries, or patient-reported outcomes can fill critical gaps. Just recognize that linkage creates its own complexity around patient matching and privacy compliance.
Integration and Linkage Challenges
Creating comprehensive longitudinal views often requires linking claims to EHRs, registries, or mortality data. But patient matching is hard—you’re often working with limited identifiers after de-identification, and error rates can be substantial if you’re using probabilistic matching algorithms.
Privacy regulations make this worse. HIPAA allows limited data sets with some identifiers retained for research, but GDPR’s consent requirements can make cross-source linkage nearly impossible in Europe without very specific legal bases.
The pragmatic approach: focus on use cases where claims alone are sufficient, or work with integrated data platforms that have already solved the linkage problem within their compliance framework. Don’t try to build your own data linkage infrastructure unless you have significant resources and legal support.
Validation and Fidelity for Synthetic Data
If you’re using synthetic data, you absolutely must validate that your synthetic populations preserve the relationships that matter for your research question. Statistical similarity on aggregate metrics isn’t enough—you need to show that causal pathways, outcome distributions, and subgroup differences are preserved.
This requires domain expertise. Work with epidemiologists and clinicians who can identify which clinical relationships are essential to preserve. Test your synthetic data against held-out real data on key outcomes. And document your validation methodology thoroughly if you plan to use synthetic data for regulatory submissions.
Regulatory Uncertainty Around Synthetic Controls
While synthetic/external controls are gaining acceptance, there’s still uncertainty about exactly what regulators will accept. The FDA has been more open than the EMA, but both agencies scrutinize these approaches carefully.
Mitigate this through early engagement. Submit your planned methodology to the FDA in pre-submission meetings or to the EMA through scientific advice procedures. Get feedback on your data sources, patient matching, confounding adjustment, and sensitivity analyses before you invest heavily in your study.
The Vendor Selection Trap
Perhaps the most common pain point: companies spend months evaluating data sources based on surface-level features (patient counts, geographic coverage, price) without understanding which capabilities actually matter for their use cases.
The result is licensing data that looks impressive in vendor presentations but fails to answer your specific research questions. Or worse, choosing based on brand recognition rather than fit-for-purpose assessment.
Before evaluating specific data partners, invest time in requirements definition. What coverage do you actually need? What analytical capabilities? What integration requirements? What compliance constraints? This clarity prevents costly mismatches and ensures you’re comparing options on dimensions that matter.
The Future: Where This Is All Heading
The trajectory is clear—aggregated and synthetic insurance data are moving from supplementary to strategic assets in pharma and medtech evidence generation. Here’s what I’m watching for 2026 and beyond.
Expanded Regulatory Acceptance
FDA is likely to provide more specific guidance on synthetic controls and external comparators, particularly for rare diseases and pediatric populations where traditional trials are challenging. We’ll see more approvals using these approaches, which will create precedents and reduce uncertainty.
The EMA is catching up. Expect additional guidance on synthetic data validation and fit-for-purpose assessments as they accumulate experience with submissions using these methods. The EHDS regulation will also clarify secondary use frameworks for aggregated health data across Europe.
Advanced Analytics and AI Integration
Machine learning models trained on synthetic insurance data will become standard for predictive analytics, treatment response modeling, and personalized medicine applications. The ability to share synthetic datasets for AI development without privacy constraints is a massive accelerator for innovation.
We’ll also see more sophisticated causal inference methods applied to claims-derived RWE—techniques like target trial emulation, instrumental variables, and regression discontinuity designs that strengthen causal conclusions from observational data.
Hybrid Data Strategies as Best Practice
The future isn’t “aggregated versus synthetic”—it’s strategic combination of both. Leading companies are building RWE platforms that use aggregated claims as the foundation for established outcomes and patterns, with synthetic augmentation for rare subgroups, scenario modeling, and AI development.
This hybrid approach maximizes the strengths of both data types while mitigating their weaknesses. And it’s the most defensible approach for regulatory submissions where you can show convergent evidence from real and synthetically-augmented analyses.
Value-Based Contracting and Outcomes Guarantees
As payers demand more real-world outcomes data to support pricing and reimbursement, aggregated claims will become essential infrastructure for value-based contracts. Pharma companies will need ongoing RWE from claims to demonstrate their products are delivering promised outcomes in real-world populations.
This shifts aggregated claims from a one-time research project to ongoing monitoring and evidence generation throughout the product lifecycle. Companies that build these capabilities early will have significant competitive advantages in payer negotiations.
Building Your Strategic Approach to Real-World Intelligence
If you’re building or enhancing your real-world evidence capabilities, here are concrete steps based on what’s actually working for successful companies:
Start with clear use cases. Don’t pursue aggregated or synthetic insurance data just because it’s available. Identify your highest-priority evidence gaps—regulatory submissions, label expansions, payer evidence, commercial insights—and ensure your data strategy can actually address those needs. Most companies skip this step and end up with data that doesn’t answer their questions.
Define requirements before evaluating options. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches and ensures you’re comparing options on dimensions that matter.
Understand the landscape dimensions. The claims data market includes dozens of sources with overlapping but distinct capabilities. Key dimensions include data recency (real-time vs. adjudicated), geographic coverage, therapeutic depth, analytical tools, integration possibilities, and cost models. Understanding these trade-offs requires expertise that most companies lack internally. Coverage breadth is necessary but not sufficient — once you have the right dataset, phenotype validation in claims data is what ensures the patient cohort you construct from it genuinely reflects your target population.
Leverage expert guidance for partner selection. The gap between understanding what claims data can do and identifying which specific sources match your needs is substantial. Navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem. Expert advisors who understand both your business objectives and the vendor landscape can accelerate your path to value while avoiding common pitfalls.
Build cross-functional teams. Successful RWE initiatives require collaboration between HEOR, regulatory, medical affairs, commercial analytics, and data science. Break down silos early and ensure everyone understands how these data types support their objectives.
Pilot before scaling. Start with a focused project to validate that your chosen approach answers your questions before committing to large-scale licensing agreements. The cost of discovering a mismatch after signing a multi-year contract is enormous.
Invest in analytics capabilities. Aggregated and synthetic data are only valuable if you can analyze them effectively. That means either building in-house expertise in real-world evidence methods (propensity scoring, causal inference, time-to-event analysis) or partnering with sources that provide analytics services alongside data access.
Engage regulators early. If you’re planning to use synthetic controls or external comparators for regulatory submissions, don’t wait until after your study is done. Get feedback through pre-submission meetings or scientific advice procedures on your methodology, data sources, and analysis plans.
Document everything. Maintain detailed documentation of your data sources, validation procedures, analysis methods, and limitations. This is essential for regulatory submissions, publications, and internal transparency about the strengths and weaknesses of your evidence.
Next Steps: Exploring Strategic Approaches to Real-World Evidence
The shift from trial-centric to RWE-augmented evidence generation is happening now. Companies that build robust capabilities around aggregated and synthetic insurance data will have faster regulatory pathways, stronger payer evidence, better commercial insights, and more efficient clinical development.
But success requires more than just licensing data. It requires understanding the landscape, making informed choices about which capabilities align with your specific needs, and building the internal processes to turn data access into actionable intelligence.
At MEDDDICAL, we help pharma and medtech companies navigate exactly these challenges. As expert advisors on real-world evidence strategy, we guide companies through the complex landscape of aggregated and synthetic data sources, helping you identify the right combination of capabilities, analytical approaches, and partnerships for your specific use cases.
Whether you need guidance on HEOR applications, synthetic cohort generation for rare disease trials, or market intelligence from real-world treatment patterns, we provide strategic consulting that accelerates your path to value while avoiding costly missteps.
Ready to explore how aggregated and synthetic insurance data could transform your RWE strategy? Contact us to discuss your specific requirements and learn about strategic approaches to real-world intelligence that align with your business objectives. We’ll help you navigate the data landscape, define your requirements clearly, and identify the right path forward for your organization.
Common Questions About Aggregated and Synthetic Insurance Data
What’s the difference between de-identified, anonymized, and synthetic data?
De-identified data has had direct identifiers removed according to standards like HIPAA Safe Harbor. Anonymized data (more commonly used in GDPR contexts) is irreversibly stripped of identifying information with very low re-identification risk. Synthetic data is generated by AI to mimic real data patterns but contains no actual patient information—it’s created from statistical models rather than derived from real records.
Can synthetic data really replace real patient data for regulatory submissions?
It depends on the application. Synthetic controls derived from real historical data are gaining acceptance for external comparators in trials, particularly for rare diseases. But regulators still scrutinize these approaches carefully and typically want to see convergent evidence from multiple sources. For exploratory analyses and AI development, synthetic data is increasingly accepted.
How do I know if aggregated claims data has sufficient quality for my research?
Ask potential data partners for detailed quality metrics: completeness percentages, validation against external benchmarks, error rates, and missingness patterns. Review data dictionaries to understand exactly what’s captured and what’s not. And consider pilot projects to validate that the data can actually answer your research questions before committing to large-scale agreements. The challenge is that quality varies significantly across sources, and surface-level features don’t reveal these differences.
What are the main GDPR compliance risks with aggregated insurance data?
GDPR’s broad definition of “identifiable” means that even aggregated data might be considered personal data if there’s any theoretical path to re-identification. The main risks are inadequate de-identification, combining your data with other sources that enable re-identification, and lack of appropriate legal bases for processing. Work with legal counsel experienced in GDPR health data provisions to ensure your compliance strategy is robust.
How should I approach data partner selection?
Start by defining your requirements clearly—coverage needs, analytical capabilities, integration requirements, and compliance constraints. Then understand the key dimensions where sources vary: data recency, geographic coverage, therapeutic depth, analytical sophistication, and cost models. The landscape includes dozens of options with overlapping but distinct capabilities. Expert guidance can help you navigate these trade-offs and identify which combination addresses your specific use cases without overpaying for capabilities you don’t need.
Sources & References
- U.S. Food and Drug Administration (2025). Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/media/190201/download
- U.S. Food and Drug Administration (2021). Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. https://www.fda.gov/media/152503/download
- U.S. Food and Drug Administration (2018). Framework for FDA’s Real-World Evidence Program. https://www.fda.gov/media/120060/download
- U.S. Department of Health and Human Services (2012). Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. https://www.hhs.gov/hipaa/for-professionals/special-topics/de-identification/index.html
- Thorpe, J.H., et al. (2020). “Synthetic and External Controls in Clinical Trials – A Primer for Researchers.” Therapeutic Innovation & Regulatory Science, 54(5), 1085-1092. https://pmc.ncbi.nlm.nih.gov/articles/PMC7218288/
- European Medicines Agency (2024). Reflection Paper on Use of Real-World Data in Non-Interventional Studies to Generate Real-World Evidence for Regulatory Purposes. https://www.ema.europa.eu/en/documents/other/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-regulatory-purposes_en.pdf
- Prilla, S., et al. (2024). “Real-World Evidence to Support EU Regulatory Decision Making—Results From a Pilot of Regulatory Use Cases.” Clinical Pharmacology & Therapeutics, 116(1), 35-43. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3355
- El Emam, K. (2022). Synthetic Data Generation for Implementing the HIPAA Expert Determination Method. Aetion Evidence Hub. https://evidence-hub.aetion.com/synthetic-data-generation-for-implementing-the-hipaa-expert-determination-method
- European Medicines Agency (2025). Real-World Evidence Framework and Catalogues Guidance. https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence
- U.S. Congress (2016). 21st Century Cures Act (Public Law 114-255), Section 3022: Real-World Evidence. https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf
- Carrigan, G., et al. (2020). “Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials.” Clinical Pharmacology & Therapeutics, 107(2), 369-377.
- Jaksa, A., et al. (2021). “Real-World Evidence to Support Regulatory Approval: Opportunities and Challenges.” Value in Health, 24(7), 857-867.
Categories: Data Enrichment for Pharma | Health Insurance Datasets
Previous Post: Pharma Product Launch Insights: Using Real-World Data for Launch Excellence
Next Post: HEOR Simulation with Aggregated Data: Budget Impact Models & Cost-Effectiveness Analysis
